Here’s What Lifted Insmed Incorporated (INSM) in Q3

1 week ago 7

Soumya Eswaran

Mon, November 17, 2025 astatine 9:10 AM CST 3 min read

Artisan Partners, an concern absorption company, released its “Artisan Small Cap Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Global equities proceed to rally successful the 3rd quarter, the play with double-digit YTD gains. Major US indices similar Russell 1000®, Russell Midcap®, and Russell 2000® reached grounds highs successful the period. In the quarter, the fund’s Investor Class money ARTSX returned 8.69%, Advisor Class money APDSX posted a instrumentality of 8.75%, and Institutional Class money APHSX returned 8.73%, compared to a instrumentality of 12.19% for the Russell 2000 Growth Index. In addition, you tin cheque the fund’s apical 5 holdings to find retired its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Artisan Small Cap Fund highlighted stocks specified arsenic Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is simply a biopharmaceutical institution that develops therapeutic products for patients with superior and uncommon diseases. The one-month instrumentality of Insmed Incorporated (NASDAQ:INSM) was 15.07%, and its shares gained 190.08% of their worth implicit the past 52 weeks. On November 14, 2025, Insmed Incorporated (NASDAQ:INSM) banal closed astatine $193.22 per share, with a marketplace capitalization of $41.209 billion.

Artisan Small Cap Fund stated the pursuing regarding Insmed Incorporated (NASDAQ:INSM) successful its 3rd 4th 2025 capitalist letter:

"Among our apical contributors were Lattice Semiconductor, Modine and Insmed Incorporated (NASDAQ:INSM). Insmed is simply a commercial-stage biotech institution focused connected superior pulmonary diseases. Its pb merchandise is ARIKAYCE®, an inhaled antibiotic that treats lung infections unresponsive to modular therapies. The institution precocious received FDA support for Brinsupri™, the archetypal once-daily oral attraction for non-cystic fibrosis bronchiectasis—a chronic and progressive lung information with constricted attraction options. With implicit 1 cardinal diagnosed patients crossed the US, Europe and Japan, Brinsupri™ addresses a large unmet need, and we expect accelerated adoption. In our view, Insmed besides has a promising pipeline, including a 3rd de-risked cause campaigner with multibillion-dollar potential. Given the company’s expanding marketplace capitalization, we began to pare backmost our CropSM position."

Insmed (INSM) Soars After Raising $650 million

Insmed Incorporated (NASDAQ:INSM) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 82 hedge money portfolios held Insmed Incorporated (NASDAQ:INSM) astatine the extremity of the 2nd quarter, which was 64 successful the erstwhile quarter. While we admit the imaginable of Insmed Incorporated (NASDAQ:INSM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.